PEG-MGF

01 · What it is

There is no evidence base for PEG-MGF. A PubMed search for `”PEG-MGF” OR “pegylated mechano growth factor”` returns five records, and not one of them is a study of the compound.

That sentence is the finding of this guide, and it should be read before anything else in it. Three of the five records concern PEGylated insulin-like growth factor 1, a different molecule ^4,5. One concerns PEGylated recombinant human growth hormone, a different molecule again ⁸. The fifth is a 2026 narrative review that names PEG-MGF among unregulated compounds encountered in clinical practice and places it explicitly in the review’s lowest evidence tier — defined by the complete absence of human studies — without reporting data on it, because there is none to report ⁹.

No in vitro study. No animal study. No pharmacokinetic study. No human exposure of any kind. This is the thinnest file in this project, thinner than TB-500’s, which at least has animal work on a closely related molecule.

What the name describes is a chemical operation performed on a peptide. PEG is polyethylene glycol, a water-soluble polymer; PEGylation is its covalent attachment to a protein or peptide, done to slow renal clearance and proteolysis and thereby extend half-life. MGF is the 24-residue C-terminal E-domain peptide of the IGF-1Ec splice variant. PEG-MGF, as the name is used commercially, denotes the second molecule carrying the first.

The rationale is sound in principle and documented in practice — for other molecules. The problem is what it is being applied to. The substrate peptide’s own central claim, that it activates muscle satellite cells, was tested by investigators at two pharmaceutical companies who found no effect on C2C12 cells, primary human skeletal muscle myoblasts or primary mouse muscle stem cells at concentrations up to 500 ng/mL, and who concluded that the results “call in to question whether there is a physiological role for MGF” ². Extending the half-life of a peptide whose activity is in dispute does not resolve the dispute. It extends the exposure.

There is a second problem, and it is the standard problem in PEGylation chemistry. Attaching a polymer to a small peptide increases half-life and frequently reduces bioactivity — this is stated as the opening premise of the work that developed a protease-cleavable linker specifically to escape the trade-off ⁵. A 24-residue peptide has little surface area to spare. Whether a PEG chain attached to it preserves whatever activity the peptide has is an empirical question, and it has not been asked.

02 · Evidence at a glance

Evidence grade

Preclinical — a floor, not a finding. No study of this compound exists at any level, in any system

Indexed records for the compound

5, none of them a study of it [4,5,8,9 and one review of the IGF-1 system]

In vitro studies

None

Animal studies

None

Human trials

None

Human subjects to date

0

Pharmacokinetic data

None for PEG-MGF; extensive for PEGylated IGF-1 ⁴

What the substrate peptide is

The 24-residue C-terminal E-domain peptide of IGF-1Ec ¹

Replication status of the substrate’s core claim

Failed ²

PEGylation trade-off

Extends half-life, “frequently comes at the cost of reduced bioactivity” ⁵

Nearest documented human data

A different molecule: PEGylated rhIGF-1, 62 healthy volunteers, half-life 140–200 h ⁴

Product identity

MGF material has been found only as a contaminant in vials labelled otherwise ⁶

Approval status

None, any jurisdiction

03 · Mechanism of action

This section describes what PEGylation does chemically and what the underlying peptide is claimed to do. It does not describe what PEG-MGF does, because nothing is known about that.

PEGylation as a pharmacokinetic intervention

Polyethylene glycol conjugation increases a molecule’s hydrodynamic radius, which reduces glomerular filtration, and shields it sterically from proteases and from antibody recognition. The size of the effect can be very large. In the one human study of a PEGylated IGF-1 conjugate, PEGylation produced a terminal half-life of 140–200 hours, against a molecule that ordinarily circulates for a fraction of that ⁴. Exposure increased approximately dose-proportionally.

The same study documented an effect that would be relevant to any PEGylated IGF-1-family molecule. Unmodified recombinant human IGF-1 almost completely suppressed growth hormone secretion through negative feedback; the PEGylated conjugate produced only a modest decrease, at the highest intravenous dose. No hypoglycaemia occurred at any dose ⁴. The authors concluded that PEGylation strongly enhances half-life, reduces negative growth hormone feedback and reduces hypoglycaemia potential.

Those are findings about a PEGylated 70-residue growth factor with a defined receptor. They are not findings about a PEGylated 24-residue fragment with no identified receptor, and this guide does not extend them.

The cost side of the trade

The premise of one of the five retrieved records is that PEGylation “increases therapeutics’ half-life but frequently comes at the cost of reduced bioactivity” ⁵. That group’s response was to insert a matrix-metalloproteinase-sensitive linker between the PEG chain and the IGF-1 molecule, so that the polymer is cleaved off in inflamed tissue and wild-type properties are restored. The conjugate as made had different binding-protein affinity, cell proliferation and endocytosis patterns from wild-type IGF-1; only cleavage restored them ⁵.

The implication for a much smaller substrate is direct. If a 30 kDa PEG chain measurably altered the behaviour of a 7.6 kDa growth factor, its effect on a peptide roughly a third that size is unlikely to be smaller, and no one has measured it.

The substrate peptide

MGF’s own mechanism is unresolved. No receptor for the E peptide has been identified in the indexed literature. Nucleolin is the only named binding partner, reported in work on cisplatin neurotoxicity ⁷. The 2014 replication attempt found no p-ERK activation in cardiac myocytes from native or stabilised peptide, alongside the null proliferation results ², while an earlier study in primary human muscle cultures did find increased proliferative life span in satellite cells from neonatal and young adult but not old adult donors ¹.

A guide to PEG-MGF is therefore a guide to a modification, of unknown effect, applied to a molecule of disputed activity, acting through an unidentified receptor.

Why the modification exists at all

The unmodified E peptide does not persist. Microencapsulation was developed for it specifically to achieve sustained delivery and maintain bioactivity ³, which is an independent acknowledgement of the same clearance problem PEGylation is meant to solve. Two different formulation strategies addressing the same limitation is reasonable evidence that the limitation is real.

04 · Key research findings

There are no research findings for PEG-MGF. What follows is what the adjacent literature establishes, each item labelled for what it is.

On PEGylated IGF-1, in humans. A single-centre, randomised, double-blind, placebo-controlled, single-ascending-dose, parallel-group study in 62 healthy volunteers compared a PEGylated recombinant human IGF-1 against unmodified rhIGF-1. The conjugate was given subcutaneously as a single injection or intravenously over 48 hours; the comparator was given subcutaneously at 50 µg/kg twice daily for four days. Half-life was 140–200 hours. Injection-site erythema was the most frequent adverse event after subcutaneous administration. No hypoglycaemia occurred. Growth hormone secretion was almost completely suppressed by unmodified rhIGF-1 and only modestly reduced by the conjugate ⁴.

This is a well-conducted first-in-man study of a different molecule, and it is the closest thing to human data anywhere near this compound. It says what PEGylation does to IGF-1. It says nothing about PEG-MGF.

On the cost of PEGylation. A protease-sensitive linker was engineered into a PEG–IGF-1 conjugate because PEGylation reduces bioactivity; the conjugate differed from wild-type in binding-protein affinity, proliferation and endocytosis, and only enzymatic cleavage of the linker restored the full suite of properties ⁵.

The trade-off is not hypothetical, and no one has established where a 24-residue peptide sits on it.

On the substrate peptide. The claimed satellite-cell effect was not reproduced across three cell types at up to 500 ng/mL, with IGF-1 and full-length IGF-1Eb responding robustly in the same experiments ². An earlier study found the effect in primary human cells from young donors and not from old ones ¹.

The molecule being PEGylated may not do the thing PEGylation is meant to make it do for longer.

On product identity. In an analysis of 17 black-market vials labelled as follistatin, MGF was among the growth-promoting peptides found in products that did not contain the labelled substance ⁶. That is the only appearance of MGF material in any analytical chemistry record. No published analysis has examined a product sold as PEG-MGF, so nothing is known about what such a product contains, what its PEG chain weighs, where it is attached, or whether the conjugation is homogeneous.

Site and degree of PEGylation determine a conjugate’s properties. For this compound, none of those parameters is documented anywhere.

On the regulatory framing. A 2026 narrative review of compounds modulating the growth hormone–IGF-1 axis names PEG-MGF among the agents encountered in clinical practice and online self-administration protocols, and stratifies the field into tiers running from regulatory-grade randomised trial data down to a complete absence of human studies ⁹. A 2026 review of approved and unapproved peptides in sports medicine makes the general point for this class: many demonstrate favourable outcomes in animal models, rigorous human safety data are scarce, and there is potential for serious harm ¹⁰. PEG-MGF does not even have the animal models.

05 · Evidence overview

06 · Safety profile

Animal data. None. No study of PEG-MGF in any species exists.

Human data. None. There is no reported human exposure to PEG-MGF in the peer-reviewed literature at any dose, by any route, for any duration.

What is genuinely unknown. Everything. That is not a rhetorical flourish; it is the accurate description of a compound with zero indexed studies. Specifically: the identity and structure of the conjugate, since PEG molecular weight, attachment chemistry and attachment site are unreported and determine everything downstream. Whether PEGylation preserves, reduces or abolishes whatever activity the substrate peptide has, given that reduced bioactivity is the expected outcome ⁵. Half-life and clearance route in any species. Tissue distribution, and whether a PEGylated peptide accumulates — PEG accumulation in tissue is a recognised concern for chronically administered conjugates and has never been examined here. Immunogenicity, including anti-PEG antibodies, which are a documented phenomenon for PEGylated therapeutics and entirely unstudied for this one. Repeat-dose toxicology, genotoxicity, reproductive toxicology and carcinogenicity: none performed. And whether any product sold under this name contains a PEGylated peptide at all, given that the only analytical examination of MGF material found it mislabelled in someone else’s vial ⁶.

The absence of adverse-event reports for this compound is not a safety signal in its favour. There are no reports because there are no studies.

07 · US regulatory status

Current as of 6 September 2026. PEG-MGF is not approved as a drug in the United States or any other jurisdiction and is not a controlled substance.

No marketing authorisation has been sought or granted anywhere. No investigational new drug programme appears in the peer-reviewed record. No agency has published an evidence review of this compound, and this guide would not rely on one for scientific content if it had.

PEGylated proteins as a class are well represented among approved drugs — PEGylated recombinant human growth hormone has been studied for dose optimisation in childhood-onset growth failure, for instance ⁸ — which establishes that the chemistry is a legitimate pharmaceutical technique and establishes nothing whatever about this application of it.

Under the World Anti-Doping Code, growth factors affecting muscle are prohibited at all times. No detection method specific to PEG-MGF appears in the indexed analytical literature. Competitors should consult the current Prohibited List directly rather than rely on secondary summaries, including this one.

08 · Limitations of the evidence

1. There is no evidence. Not thin evidence, not preclinical-only evidence, not evidence of poor quality. Five records mention the term; none studies the compound ^4,5,8,9. Every other guide in this project has something to grade. This one has an absence.

1. The Preclinical grade is a floor, not a finding. The grading rubric’s lowest tier describes compounds with in vitro and animal data only. PEG-MGF has neither. It receives the lowest available grade because there is nowhere lower, and the grade should not be read as implying that preclinical support exists.

1. The substrate peptide’s activity is itself contested. The satellite-cell claim failed a well-designed replication attempt across three cell types ², with one positive result confined to cells from young donors ¹. A modification to a molecule of uncertain activity inherits that uncertainty and adds its own.

1. PEGylation is expected to reduce activity, and no one has checked. The premise is stated plainly in the conjugation literature ⁵. For a 24-residue peptide, the proportional impact of a polymer chain is larger than for a full-length protein, and it is unmeasured.

1. The conjugate is chemically undefined in the public record. PEG molecular weight, attachment site, linker chemistry, degree of substitution and batch homogeneity all determine a conjugate’s pharmacology. None is published for any product sold under this name.

1. Human data from a different molecule cannot be borrowed. The 62-volunteer PEGylated rhIGF-1 study ⁴ is good evidence about PEGylated rhIGF-1. Treating it as informative about PEG-MGF would be the same error this project has flagged for TB-500 and for CJC-1295 No-DAC, and it is a larger error here because the molecules differ in size, sequence, receptor and established activity.

1. Publication bias cannot apply to a literature that does not exist, but the reverse problem does: claims about this compound circulate entirely outside the peer-reviewed record, which means there is nothing to weigh them against.

1. Material identity is wholly unestablished. The single analytical record involving MGF found it as a contaminant in mislabelled vials ⁶. No published analysis has examined a product sold as PEG-MGF.

1. This guide asserts absence from the indexed record. That assertion is checkable and was checked on 6 September 2026. Unindexed or unpublished work cannot be excluded and cannot be cited.

09 · References

1. Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev. 2011 Apr;132(4):154–162.

   PMID 21354439 ↗

2. Fornaro M, Hinken AC, Needle S, et al. Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells. Am J Physiol Endocrinol Metab. 2014 Jan 15;306(2):E150–E156.

   PMID 24253050 ↗

3. Niu X, Chen P, Jia X, et al. Microencapsulation of mechano growth factor E peptide for sustained delivery and bioactivity maintenance. Int J Pharm. 2014 Jul 20;469(1):214–221.

   PMID 24768406 ↗

4. Kletzl H, Guenther A, Höflich A, et al. First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I. Growth Horm IGF Res. 2017 Apr;33:9–16.

   PMID 28110155 ↗

5. Braun AC, Gutmann M, Mueller TD, Lühmann T, Meinel L. Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate. J Control Release. 2018 Jun 10;279:17–28.

   PMID 29634992 ↗

6. Reichel C, Gmeiner G, Thevis M. Detection of black market follistatin 344. Drug Test Anal. 2020.

   PMID 31758732 ↗

7. Podratz JL, Tang JJ, Polzin MJ, et al. Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity. Exp Neurol. 2020 Sep;331:113376.

   PMID 32511954 ↗

8. Wu Y, et al. Dose optimization of PEG-rhGH therapy to improve growth outcomes of childhood-onset growth failure. Growth Horm IGF Res. 2025 Oct.

   PMID 40974917 ↗

9. Dominikowski A, Rękoś K, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026.

   PMID 42395176 ↗

10. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026.

    PMID 41966639 ↗